[1st experiences with Adriamycin, a new cytotoxic antibiotic, in combination chemotherapy of malignant tumors].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002277:Carcinoma / Q000188:drug therapy; D004357:Drug Synergism; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008168:Lung / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011241:Prednisone / Q000008:administration & dosage; D011859:Radiography; D012075:Remission, Spontaneous; D012509:Sarcoma / Q000188:drug therapy; D013752:Tetracycline / Q000008:administration & dosage*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D000903:Antibiotics, Antineoplastic; D014750:Vincristine; D013752:Tetracycline; D011241:Prednisone
Erste ERfahrungen mit Adriamycin, einem neuen zytotoxischen Antibiotikum, in der Kombinationschemotherapie maligner Tumoren.